Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8973700rdf:typepubmed:Citationlld:pubmed
pubmed-article:8973700lifeskim:mentionsumls-concept:C0025266lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0138741lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0456603lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C1996904lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0439810lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C1521733lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C1880497lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0392752lld:lifeskim
pubmed-article:8973700lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:8973700pubmed:issue6A Suppllld:pubmed
pubmed-article:8973700pubmed:dateCreated1997-1-17lld:pubmed
pubmed-article:8973700pubmed:abstractTextThe combined use of total prostate-specific antigen (PSA), clinical stage, and Gleason score accurately predicts final pathologic stage for men with clinically localized prostate cancer. Recently, the free/ total PSA ratio has been proposed as an adjunct for early detection of prostate cancer. We examined the association between free/total PSA and pathologic stage.lld:pubmed
pubmed-article:8973700pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8973700pubmed:languageenglld:pubmed
pubmed-article:8973700pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8973700pubmed:citationSubsetIMlld:pubmed
pubmed-article:8973700pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8973700pubmed:statusMEDLINElld:pubmed
pubmed-article:8973700pubmed:monthDeclld:pubmed
pubmed-article:8973700pubmed:issn0090-4295lld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:FOLLlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:LudererA AAAlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:CarterH BHBlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:EpsteinJ IJIlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:PartinA WAWlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:JonesK AKAlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:PannekJJlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:SubongE NENlld:pubmed
pubmed-article:8973700pubmed:authorpubmed-author:MarschkeP LPLlld:pubmed
pubmed-article:8973700pubmed:issnTypePrintlld:pubmed
pubmed-article:8973700pubmed:volume48lld:pubmed
pubmed-article:8973700pubmed:ownerNLMlld:pubmed
pubmed-article:8973700pubmed:authorsCompleteYlld:pubmed
pubmed-article:8973700pubmed:pagination51-4lld:pubmed
pubmed-article:8973700pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:meshHeadingpubmed-meshheading:8973700-...lld:pubmed
pubmed-article:8973700pubmed:year1996lld:pubmed
pubmed-article:8973700pubmed:articleTitleThe role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.lld:pubmed
pubmed-article:8973700pubmed:affiliationJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institution, Baltimore, Maryland 21287-2101, USA.lld:pubmed
pubmed-article:8973700pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8973700pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8973700pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8973700pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed